Introduction
The 2 -adrenergic receptor ( 2AR) is a G-protein-coupled cell surface receptor that is the key target for the 2 -agonist drugs used as bronchodilators and -blockers (Liggett 2000) . The relation between polymorphism of the 2AR receptor and therapeutic response has been reported (Erickson and Gravis 2001; Ligget 1997; Makimoto et al. 2001) . In the human population, nonsynonymous single-5Ј-Cy3-GTC AGG CCT TAC/5Ј-Cy5-TCA GGC CTT AT (Fig. 1) . Each PCR product was desalted using a multiscreen plate (Millipore, Bedford, MA, USA). The protocols were then run at predetermined temperatures on a NanoChip system according to the Nanogen application guide. Samples were scored automatically according to the following threshold: heterozygote Ͻ 1 : 2 Ͻ no designation Ͻ 1 : 5 Ͻ Homozygote. The DHPLC instrument was the WAVE system (Transgenomic, Omaha, NE, USA). Unpurified PCR amplicons were heated at 95°C for 5 min and cooled slowly over 45 min to 25°C in a thermocycler. The reactions were then run at predetermined temperatures on the WAVE system, as described (Shinka et al. 2001) . The resultant chromatograms were compared for variation in shape and/or retention time. For direct sequencing, PCR products were purified using the QIA Quick PCR Purification Kit (Qiagen, Valenica, CA, USA) and were sequenced with an automated sequencer (377XL, Applied Biosystems, Foster City, CA, USA) using the ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit, as described (Kikuchi et al. 2000) . Data were analyzed with Sequencher software (Hitachi Software, Tokyo, Japan). For positions Ϫ47T/C, 46A/G, and 79C/G, we conducted the electronic microchip assay, DHPLC, and direct sequencing methods until identical data were obtained for all three methods. The 491C/T genotyping was conducted by electronic microchip assay and direct sequencing. The agreement data between the systems were defined as the final data (allele call). The agreement rate was calculated as the correspondence rates of the first data set with the final data (allele call). Figure 2 shows the 46A/G results by electronic microchip assay (A), DHPLC (B), and direct sequencing (C). The upper part of Fig. 2A shows a portion of the real-time analytic screen. If we selected #18 as the hetero control, the scoring was conducted automatically according to the previous threshold. Figure 2B and Fig. 2C show typical patterns obtained with DHPLC and direct sequencing. The agreement rates of the first data set with the final agreement data (allele calls) were 99.7% (332/333), 99.2% (246/248), and 96.7% (329/340). The percentages of no allele designation (ND) were 2.06% (7/340), 2.75% (7/255), and 0.00% (0/340) for the electronic microchip assay, DHPLC, and direct sequencing, respectively (Table 1) . The DHPLC and direct sequence disagreement data were caused by human error in manual analysis. The total agreement ratio was the highest among the three tested methods. The 491C/T results by the electronic microchip assay agreed with those from direct sequencing, even in the presence of nonspecific PCR products. Therefore, the electronic microchip system would be a powerful tool for clinical use.
Results and discussion
In the present study, we found three samples that had novel haplotypes, which was supported by the DHPLC result. The chromatography patterns of the samples by DHPLC disagreed with that of previously reported haplotypes (Drysdale et al. 2000) . The putative haplotypes did not show linkage disequilibrium between Ϫ47T/C and 79C/G. The Ϫ47T/C SNP site is located at the 2AR regulation region and has been reported to show linkage disequilibrium with 79C/G. Parola and Kobilka (1994) (Drysdale et al. 2000) T G C C 57.5 allel frequency (%) C G G C 10.0 #11, 32, 76 T/C A/G C/C C/C DHPLC, Denaturing high-performance liquid chromatography; SNP, single-nucleotide polymorphism ͖ reported that the peptide product of a 5Ј leader cistron in the 2AR mRNA inhibited receptor synthesis. McGraw et al. (1998) reported that the Ϫ47T/C variation may represent the genetic basis of variable physiologic sympathetic responses, variation in disease phenotypes, or differences in therapeutic efficacy of -agonists or antagonists. Further studies are needed to prove that these three samples contain novel haplotypes. The relationship between the haplotype of 2AR and therapeutic response and disease should also be investigated.
